Operating Company Healthcare

Carlin Consumer Health

New York, New York, United States

Healthcare platform launched by sponsor investors Hildred Capital Management, Bourne Partners Strategic Capital, and The Emerson Group to establish a consumer health business and acquire and commercialize over-the-counter (OTC) brands.

Focus Areas
Consumer Health, Over-the-counter (OTC) Pharmaceuticals, Digestive Health

Tracked deals

3

3 tracked deals across 2022-2024.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

1 addon · 1 buyout · 1 divestiture

Carlin Consumer Health Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Carlin Consumer Health. 1 2022 1 2023 1 2024

Supporting Data

Recent Transactions

  • Carlin Consumer Health Acquires Penetrex from Wellbeam Consumer Health
    April 30, 2024
    Buyer
    Carlin Consumer Health
    Target
    Penetrex
    Seller
    Wellbeam Consumer Health
    Industry
    Healthcare Services
    Location
    New York, United States
    Type
    Buyout

    Carlin Consumer Health acquired PENETREX (Penetrex) from Wellbeam Consumer Health. Penetrex will become a brand within the Carlin Consumer Health portfolio; financial terms were not disclosed.

  • Carlin Consumer Health Acquires Infirst USA Holdings, LLC
    October 24, 2023
    Buyer
    Carlin Consumer Health
    Target
    Infirst USA Holdings, LLC
    Industry
    Consumer Products
    Location
    Connecticut, United States
    Type
    Addon

    Carlin Consumer Health, a PE‑sponsored consumer health platform, has acquired Infirst USA Holdings, LLC, the parent of Infirst Healthcare Inc., the marketer of Mylanta and Mylicon under license from McNeil Consumer Pharmaceuticals. Infirst will become a wholly owned subsidiary of Carlin; the company is based in Westport, Connecticut and ships from a warehouse in Plainfield, Indiana. Financial terms were not disclosed.

  • Carlin Consumer Health Acquires Zegerid OTC from Bayer
    February 1, 2022
    Buyer
    Hildred Capital Management, LLC, Bourne Partners Strategic Capital, The Emerson Group
    Target
    Zegerid OTC
    Seller
    Bayer AG
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Divestiture

    Hildred Capital, Bourne Partners Strategic Capital and The Emerson Group launched Carlin Consumer Health and acquired the Zegerid OTC brand from Bayer AG to establish a consumer health/OTC platform. The investors plan to invest in marketing, sales and product development to grow the Zegerid brand across U.S. retail channels; financial terms were not disclosed.

Related Acquisition Pages

Consumer Products Buyers & Acquisitions 1 tracked deal by Carlin Consumer Health. Healthcare Services Buyers & Acquisitions 1 tracked deal by Carlin Consumer Health. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Carlin Consumer Health. Acquisitions in Connecticut 1 tracked deal by Carlin Consumer Health. Acquisitions in New York 1 tracked deal by Carlin Consumer Health.

Related articles

Selling a company? Get in front of buyers like Carlin Consumer Health

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →